Orphan Drugs Research & Commercialization Conference
- 最後更新：
- 2013-05-02 11:22:17
- 活動時間：
- 2013-05-08 ~ 2013-05-10
- 活動地點：
- Boston, MA
- 報名時間：
- 0000-00-00 ~ 0000-00-00
- 活動費用：
活動介紹
Dear Colleague,
Philip Astley-Sparke, who was recently appointed President U.S. of uniQure B.V., will give the featured presentation, "Is Gene Therapy About to Deliver for the Investor?" at GTC's Orphan Drugs Research & Commercialization Conference. uniQure's Glybera, a gene therapy for the treatment of lipoprotein lipase deficiency, became the first approved gene therapy in the Western world when it was approved by the European Union in November 2012. Mr. Astley-Sparke will discuss why gene therapy is now ready for prime time and how marketable such an expensive treatment is for rare disease patients
GTC is proud to announce the Orphan Drugs Research & Commercialization Conference on May 8-10, 2013 in Boston, MA. This meeting provides opportunities for industry leaders, members of academia, government regulators, and patient groups to dialogue about strategies to improve orphan drug research, pricing, reimbursement, access, and other key topics.
Keynote speakers include Steve Groft, the Director of the Office of Rare Diseases Research (ORDR) at the National Institutes of Health (NIH), and Michael Scott, Chairman of the Board of Directors at the National Organization for Rare Disorders (NORD).
The Orphan Drugs Research & Commercialization conference is part of Drug Discovery Summit 2013, which features the following co-located conferences that will run concurrently:
. 3rd Epigenetics in Drug Discovery
. 7th Drug Design & Medicinal Chemistry
. 6th Imaging in Drug Discovery & Development
Register today to save your spot!
Register 3 people for the price of 2! Use discount code RCDVB.